Table 3.
Distribution of AT8‐positive NFTs in all AGD‐TA cases.
| Neurofibrillary tangles | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braak NFTstage*/Thal Aβ phase | Lewy body disease subtype | Argyrophilic grain disease stage | TDP‐43 pathology | Superior frontal cortexb | Caudate nucleus | Putamen | Globus pallidus | Subthalamic nucleus | Substantia nigra | Oculomotor nucleus | Pontine nucleus | Inferior olivary nucleus | Dentate nucleus in cerebellum | ||
| AGD‐TA 1 | I/3 | Brain stem type | I | 0 | − | ++++ | − | − | − | + | − | − | − | − | |
| AGD‐TA 2 | II/0 | 0 | I | 0 | +++ | − | ++++ | +++ | n.a. | + | +++++ | + | − | − | |
| AGD‐TA 3 | II/3 | 0 | II | 0 | n.e. | +++ | +++ | + | n.a. | + | +++ | +++ | +++ | − | |
| AGD‐TA 4 | II/0 | 0 | I | 0 | +++ | − | ++ | +++ | n.a. | + | − | ++ | + | + | |
| AGD‐TA 5 | II/0 | 0 | I | 0 | +++ | +++ | +++ | + | ++ | ++ | ++ | ++ | +++ | + | |
| AGD‐TA 6 | II/5 | 0 | III | 0 | n.e. | +++ | ++++ | + | +++++ | +++++ | +++ | +++ | − | +++ | |
| AGD‐TA 7 | II/3 | 0 | II | 0 | n.e. | +++ | +++ | +++ | +++ | ++++ | +++++ | +++ | +++ | +++ | |
| AGD‐TA 8 | II/0 | 0 | III | 0 | +++ | +++++ | +++++ | ++++ | +++++ | +++++ | +++++ | + | + | ++ | |
| AGD‐TA 9 | I/1 | 0 | III | Amygadala type | ++++ | +++ | + | +++ | ++ | + | − | +++ | +++ | +++ | |
| AGD‐TA 10 | IV/3 | Limbic type | III | Limbic type | n.e. | +++++ | ++++ | ++++ | ++++ | ++++ | +++ | +++ | ++ | +++ | |
| AGD‐TA 11 | II/0 | 0 | III | Amygdala type | ++++ | +++++ | ++++ | +++ | +++++ | +++++ | ++++++ | +++ | ++ | +++ | |
| (%) | 85.7 | 81.8 | 90.9 | 90.9 | 87.5 | 100.0 | 72.7 | 90.9 | 72.7 | 72.7 | |||||
a
Braak NFT stage determined with RD3 immunohistochemistry is shown.
b
The number of NFTs in the superior frontal cortex was assessed when the case did not have Aβ deposits in the region. Semiqunatitative NFT stages 0 to 7 correspond to – to +++++++ (see text). n.e. = not examined; n.a. = not available.